超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

再鼎醫(yī)藥是一家致力于研究、開發(fā)和銷售創(chuàng)新藥物的制藥企業(yè)。再鼎醫(yī)藥針對目前尚無良好治療手段的疾病領(lǐng)域開發(fā)新藥，以改善全球病人的生活質(zhì)量。再鼎醫(yī)藥通過內(nèi)部研發(fā)和授權(quán)許可等方式建立全面的產(chǎn)品線。我們希望公司開發(fā)的新藥能夠遏制疾病，并為患者帶來顯著療效。

再鼎醫(yī)藥創(chuàng)建于2013年，公司擁有一支在全球制藥企業(yè)和研發(fā)機構(gòu)富有經(jīng)驗的世界級管理團(tuán)隊。這支擁有卓越成功經(jīng)驗的創(chuàng)始人團(tuán)隊被譽為中國快速發(fā)展的生物技術(shù)產(chǎn)業(yè)的先驅(qū)，曾帶領(lǐng)多個成品成功獲得中國和美國食品藥品監(jiān)督管理局的認(rèn)可。這支團(tuán)隊最先在中國嘗試新藥快速審批途徑并獲得批準(zhǔn)，同時也與多個跨國制藥巨頭建立了長期的戰(zhàn)略合作伙伴關(guān)系。在再鼎醫(yī)藥，團(tuán)隊將繼續(xù)投身于在中國為世界開發(fā)高質(zhì)量的創(chuàng)新藥。

再鼎醫(yī)藥獲得數(shù)家生物醫(yī)藥領(lǐng)域的全球頂級投資機構(gòu)的支持，包括啟明創(chuàng)投基金，凱鵬華盈中國基金，紅杉資本和泰福資本。這些投資機構(gòu)都將堅定地支持再鼎醫(yī)藥成長為生物醫(yī)藥領(lǐng)域的國際領(lǐng)先企業(yè)。

Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. Our vision is to address the largest unmet medical needs and transform patients’ lives around the world. We take a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline. We believe our drug candidates can be truly disease modifying and bring significant benefits to patients.

The company was founded in 2013 by a group of industry veterans. The founders are known as pioneers in China’s fast advancing biotech industry with a proven track record for successful Chinese CFDA and US FDA filings and approvals. Our senior management team introduced fast regulatory approval pathways in China and developed a variety of partnership models with multinational pharmaceutical companies. We endeavor to conduct world class clinical development in China and beyond.

Zai Lab has strong backing from a leading group of healthcare investors including Qiming Venture Partners, Kleiner Perkins Caufield & Byers, Sequoia Capital and TF Capital. Our investors are committed to support Zai Lab to become a global biopharmaceutical leader based in China.